Economic burden of mucormycosis in the United States: can a vaccine be cost-effective? - Wikidata - wikimedia - TriplyDB

Economic burden of mucormycosis in the United States: can a vaccine be cost-effective?

Economic burden of mucormycosis in the United States: can a vaccine be cost-effective?

http://www.wikidata.org/entity/Q37475459

about

Sporangiospore size dimorphism is linked to virulence of Mucor circinelloides Hospital days, hospitalization costs, and inpatient mortality among patients with mucormycosis: a retrospective analysis of US hospital discharge data.Recent advances in the treatment of mucormycosis.Human Fungal Pathogens of Mucorales and Entomophthorales.A zebrafish larval model reveals early tissue-specific innate immune responses to Mucor circinelloides.Translational Development and Application of (1→3)-β-d-Glucan for Diagnosis and Therapeutic Monitoring of Invasive Mycoses.The cost of treating mucormycosis with isavuconazole compared with standard therapy in the UK.Macrophage-Microbe Interactions: Lessons from the Zebrafish Model.Robust Phagocyte Recruitment Controls the Opportunistic Fungal Pathogen Mucor circinelloides in Innate Granulomas In Vivo.

P2860

Q27349560-D12F4357-1698-4C21-ABDC-72FFAE48CDE0 Q30829283-0704FC5B-E838-4D2E-B60E-7513B5887718 Q34161213-27AD57AA-005E-4095-9F3F-8594BDDE0B28 Q35245238-20D97B3E-07CE-49CD-9B72-6B8C93BB43E7 Q36245166-8970D8CC-CBF5-4A07-8650-D917B7438AB7 Q38679742-AF923A74-D722-47E8-B6D6-FB010D0781BD Q38758268-95DCAEAF-91EA-4FB3-B125-2C9ADB22436D Q47126966-041C65A7-5441-418F-AE46-6F5A86F623EB Q55043119-C06CACD0-3867-44C9-9AAF-824FADF2DC76

P2860

Economic burden of mucormycosis in the United States: can a vaccine be cost-effective?

http://www.wikidata.org/entity/Q37475459

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on January 2009

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Economic burden of mucormycosis in the United States: can a vaccine be cost-effective?

@en

Economic burden of mucormycosis in the United States: can a vaccine be cost-effective?

@nl

type

label

Economic burden of mucormycosis in the United States: can a vaccine be cost-effective?

@en

Economic burden of mucormycosis in the United States: can a vaccine be cost-effective?

@nl

prefLabel

Economic burden of mucormycosis in the United States: can a vaccine be cost-effective?

@en

Economic burden of mucormycosis in the United States: can a vaccine be cost-effective?

@nl

P1433

Q37475459-D26E7D80-7A02-4657-95E2-47DCE2163A61

P1476

Q37475459-0C236ECE-AFFC-481A-9010-B28D2CEE917C

P2093

Q37475459-1E0B20AE-9FD8-4DDE-9824-C6B53530D9CD

Q37475459-39015AAC-B6A6-484E-9197-1B4E7ACBC04D

Q37475459-5916D1EF-38C5-4BA9-9601-709CFEF51581

Q37475459-E9D1B396-B652-4740-8BB4-DDD5632E7881

P2860

Q37475459-09C5B0FC-0790-4D3F-99E8-108CB4924F49

Q37475459-14F3036B-0C66-4DF7-A4F9-DF4C62A54866

Q37475459-1E1A3BC9-8542-4E94-8B54-3F3E95E6AF34

Q37475459-21A333D5-04C0-4644-B6ED-CEFC5D243EFA

Q37475459-2C41C3E7-24C7-456E-83F5-8EBC96C437E6

Q37475459-37DAD2A4-B66E-4678-81B9-66D42065FD8D

Q37475459-383F4110-CB74-4DC3-8CBA-0263BF1527FB

Q37475459-3AA191CC-6FC2-414E-BCAE-2615DF74F55A

Q37475459-3ED4316E-072C-4AA1-BA7E-25263DC3DAFC

Q37475459-4EFD6BC8-20F1-4AD8-A980-E4C35DC3BC5C

P304

Q37475459-3B298D63-EE07-42C4-B35F-253CA9F290DF

P31

Q37475459-F8936E53-B6B4-4E15-887A-BD5F43D20A44

P356

Q37475459-B662542F-92EF-4B64-9DB5-5D3720BC233D

P433

Q37475459-C2AABF3B-50F2-4071-9951-131E3F82704C

P478

Q37475459-3BD2D08B-54B3-4A32-8212-332350C901F3

P577

Q37475459-0C1DCA86-8704-43BB-81AA-EAF11FAEBF68

P5875

Q37475459-B411EC3D-0CE0-4B84-9EEE-3AF6DEC7B700

P698

Q37475459-59858B84-D419-4FD5-B2AC-5B38E6EFC0FE

P921

Q37475459-C258E6C0-BEC8-4FD4-A383-E31F386F90B6

P932

Q37475459-371EE98E-455A-4673-A167-4969CF16F9EB

P356

13693780802326001

P1433

Medical Mycology

P1476

Economic burden of mucormycosis in the United States: can a vaccine be cost-effective?

@en

P2093

Ashraf S Ibrahim

http://www.w3.org/2001/XMLSchema#string

Brad Spellberg

http://www.w3.org/2001/XMLSchema#string

John E Edwards

http://www.w3.org/2001/XMLSchema#string

Richard Bryant

http://www.w3.org/2001/XMLSchema#string

P2860

Zygomycetes in human disease

Novel perspectives on mucormycosis: pathophysiology, presentation, and management.

Mucormycosis in allogeneic bone marrow transplant recipients: report of five cases and review of the role of iron overload in the pathogenesis.

Pneumonia in HIV-infected patients: a case-control survey of factors involved in risk and prevention.

Long-term health-related quality of life in survivors of sepsis. Short Form 36: a valid and reliable measure of health-related quality of life.

Zygomycosis in a tertiary-care cancer center in the era of Aspergillus-active antifungal therapy: a case-control observational study of 27 recent cases.

Epidemiology and outcome of zygomycosis: a review of 929 reported cases.

Overview of the diagnosis and management of diabetic ketoacidosis.

Epidemiology and outcome of mould infections in hematopoietic stem cell transplant recipients.

Transplant center characteristics and clinical outcomes after hematopoietic stem cell transplantation: what do we know?

P304

592-600

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1080/13693780802326001

http://www.w3.org/2001/XMLSchema#string

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

47

http://www.w3.org/2001/XMLSchema#string

P577

2009-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

23261392

http://www.w3.org/2001/XMLSchema#string

P698

18798118

http://www.w3.org/2001/XMLSchema#string

P921

Ameeriga Ütisriigiq

P932

2793326

http://www.w3.org/2001/XMLSchema#string